Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01240005

Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma

A Phase I/II Evaluation of Cytokine Induced Killer Cells Stimulated by DC(DCIK) Immunotherapy in Patients With Renal Cell Carcinoma

Sponsor: Qingdao University

Conditions Renal Cell Carcinoma

Interventions DCIK

Updated 4 times since 2017 Last updated: Nov 12, 2010 Started: Jan 31, 2011 Primary completion: Dec 31, 2012 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Renal Cell Carcinoma and is currently ongoing. Qingdao University leads this study, which shows 4 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qingdao University

Data source: Qingdao University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Qingdao, China